Physician profile
Robert Fox
NPI 1508869819
$2,063.26
in general payments reported to CMS, 2019-2025
18 companies · $685 in 2025
The $685 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.12 · 2020: $36.51 · 2021: $301 · 2022: $239 · 2023: $358 · 2024: $404 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,446.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $391.40 | 2020-2025 | |
| Abbvie INC. | $345.33 | 2022-2025 | |
| Alcon Vision LLC | $234.22 | 2021-2025 | Unity |
| Mallinckrodt Hospital Products INC. | $231.94 | 2023-2024 | Acthar |
| Allergan, INC. | $189.35 | 2021-2022 | |
| Astellas Pharma US INC | $148.57 | 2025 | Izervay |
| Tarsus Pharmaceuticals, INC. | $137.58 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $106.92 | 2023 | Tyrvaya |
| Horizon Therapeutics Plc | $67.63 | 2021-2022 | |
| Dompe US, INC. | $36.30 | 2025 | Oxervate |
| Apellis Pharmaceuticals, INC. | $32.74 | 2023 | |
| Ani Pharmaceuticals, INC. | $28.12 | 2024 | Purified Cortrophin Gel |
| Ibsa Pharma INC. | $24.55 | 2019 | |
| Genentech USA, INC. | $21.99 | 2021 | |
| Glaukos Corporation | $21.74 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $16.75 | 2020 | |
| Omeros Corporation | $14.57 | 2019 | |
| Ocular Therapeutix, INC. | $13.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.